Results of DIAN-TU Familial AD Trial
“An international clinical trial evaluating whether two investigational drugs can slow memory loss and cognitive decline in people in the early stages of a rare, inherited form of Alzheimer’s disease has yielded disappointing results, an initial analysis of the data has shown. However, the researchers continue to explore data from the trial’s cognitive and clinical outcomes, and await analyses of biomarkers and other information so they can further understand the study’s results.”
A detailed analysis of the trial’s data will be presented for the first time April 2 at the AAT-AD/PD™ Advances in Alzheimer’s and Parkinson’s Therapies Focus Meeting in Vienna, followed by presentations at the Alzheimer’s Association International Conference in Amsterdam in July.
Click the button below to browse the full AAT-AD/PD™ 2020 interactive scientific program.